Rapport Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Rapport Therapeutics, Inc. (RAPP) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$76.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-05
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$56.62M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$19.86M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$33.76M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$26.93M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$111.48M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$78.31M.
- Rapport Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$34.79M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$56.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$76.47M 10-Q · filed 2026-08-05 | -$110.23M derived: sum of 3 quarters · filed 2026-08-05 | -$137.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$19.86M 10-Q · filed 2026-05-07 | -$53.62M derived: sum of 2 quarters · filed 2026-05-07 | -$80.55M derived: sum of 3 quarters · filed 2026-05-07 | -$107.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$33.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$60.69M derived: sum of 2 quarters · filed 2026-03-10 | -$87.42M derived: sum of 3 quarters · filed 2026-08-05 | -$111.48M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$26.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$53.66M derived: sum of 2 quarters · filed 2026-08-05 | -$77.72M 10-Q · filed 2025-11-06 | -$97.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$26.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$50.80M 10-Q · filed 2026-08-05 | -$70.78M derived: sum of 3 quarters · filed 2026-08-05 | -$88.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$24.06M 10-Q · filed 2026-05-07 | -$44.04M derived: sum of 2 quarters · filed 2026-05-07 | -$61.58M derived: sum of 3 quarters · filed 2026-05-07 | -$79.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$19.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$37.52M derived: sum of 2 quarters · filed 2026-03-10 | -$55.64M derived: sum of 3 quarters · filed 2026-03-10 | -$78.31M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$17.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$35.66M derived: sum of 2 quarters · filed 2025-11-06 | -$58.33M 10-Q · filed 2025-11-06 | -$71.85M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$18.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$40.79M 10-Q · filed 2025-08-07 | -$54.31M derived: sum of 3 quarters · filed 2025-08-07 | -$63.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$22.67M 10-Q · filed 2025-05-08 | -$36.19M derived: sum of 2 quarters · filed 2025-05-08 | -$44.90M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$22.23M derived: sum of 2 quarters · filed 2025-03-11 | -$34.79M 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$21.27M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$12.56M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |